Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Evolution of Blood-Brain Barrier Penetrant AAV Capsids in Non-Human Primates Using a Multiplexed Transcription Dependent Capsid Engineering Platform

Download PDF